An editorial chronicle, not a clinic.

What this site is

Tirzepatide Medicine is an independent editorial chronicle of the tirzepatide clinical literature. We summarize, in plain prose, the published evidence on a single FDA-approved peptide medicine — the trials, the mechanism, the dosing, the safety profile. We update the site as new pivotal trials publish.

We model the site on long-form medical journalism: short, declarative summaries; citations to primary sources; no advocacy and no anecdote. Every numerical claim we make traces back to a peer-reviewed paper, a regulatory document, or a registered trial record. The full reference list is on the references page.

What this site is not

• Not a clinic. We do not diagnose, prescribe, or counsel patients. If you are considering or taking tirzepatide, your prescribing clinician is the relevant authority on your specific situation.
• Not a vendor. We do not sell tirzepatide or any other product. We do not link to vendors. We are not affiliated with any pharmaceutical manufacturer, compounding pharmacy, telehealth platform, or supplement company.
• Not a marketing site. We are not commissioned by, funded by, or operated on behalf of Eli Lilly and Company or any other drug manufacturer. The trials we summarize were largely sponsored by the manufacturer — we say so each time it is material.
• Not a personal account. This site does not host first-person testimonials, before-and-after photos, or user reviews. The evidence base is large enough that anecdote is unnecessary.

Editorial standards

Three rules govern what appears here:

1. Every quantitative claim cites a source. Effect sizes, sample sizes, hazard ratios, doses, half-life — all link to a specific paper.
2. No medical advice. We describe what trials measured. We do not recommend what any individual should do with their body.
3. Brand names are avoided where possible. Tirzepatide is sold under multiple brand names; we use the generic chemical name, except in two contexts: (a) the page summarizing FDA approvals lists the trade names regulators approved; (b) the references list reproduces titles of papers as published.

We do our own work, on our own schedule, with the expressed goal of being more reliable than a Google snippet and faster to read than a journal abstract. If we get something factually wrong, we will correct it — see contact.